Skip to main content

Table 2 Correlation of promoter methylation with clinical and histologic parametrs, HPV status and microsatellite instability in CC patients

From: Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome

 

Methylated genes

Parameter

Overall

CDH1

DAPK

RARB

HIC1

FHIT

RASSF1A

APC

CDKN2A

MGMT

BRCA1

Histology

           

   SCC (N = 77)

66

45

36

24

12

9

5

5

6

4

3

   AC (N = 5)

5

0

1

0

3

0

1

4

1

0

2

Significance

P = 1.00

P = 0.02

P = 0.372

P = 0.315

P = 0.040

P = 1.00

P = 0.323

P = 0.0003

P = 0.367

P = 1.00

P = 0.028

Stage

           

   I (N = 17)

10

6

5

3

5

0

4

2

2

0

0

   II (N = 19)

19

13

12

5

3

3

2

2

1

0

2

   III-IV (N = 46)

42

16

20

16

7

6

0

5

4

4

3

Significance

P = 0.0005

P = 0.0005

P = 0.129

P = 0.394

P = 0.460

P = 0.279

P = 0.003

P = 1.00

P = 0.759

P = 0.395

P = 0.397

Size of tumor

           

   1–5 cm (N = 32)

28

20

13

10

8

3

4

4

1

0

1

   ≥ 6 cm (N = 38)

34

21

19

13

6

4

1

3

4

2

2

Significance

P = 1.000

P = 0.540

P = 0.433

P = 0.793

P = 0.337

P = 1.00

P = 0.171

P = 0.695

P = 0.366

P = 0.497

P = 1.000

Age (yrs)

           

   ≤ 40 (N = 32)

28

17

17

12

6

6

1

1

3

3

1

   41–50 (N = 17)

12

8

5

5

3

0

2

0

1

1

1

   51–60 (N = 13)

13

6

5

6

3

2

1

6

1

0

3

   > 60 (N = 20)

18

14

10

1

3

1

2

2

2

0

0

Significance

P = 0.113

P = 0.439

P = 0.400

P = 0.021

P = 0.956

P = 0.169

P = 0.600

P = 0.0004

P = 1.000

P = 0.467

P = 0.053

Clinical Outcome

           

Alive (N= 39)

30

18

19

8

7

3

5

4

2

0

0

DOC (N= 43)

41

27

18

16

8

6

1

5

5

4

5

Significance

0.015

P = 0.131

P = 0.533

P = 0.097

P = 0.939

P = 0.487

P = 0.097

P = 1.000

P = 0.436

P = 0.118

P = 0.056

Treatment response¶

           

CR (N= 21)

19

11

15

3

4

1

2

3

2

0

0

DOC/PR (N = 26)

24

15

10

12

4

3

1

4

3

2

2

Significance

1.000

0.716

0.024

0.020

1.000

0.617

0.579

1.000

1.000

0.495

0.495

HPV type

           

   HPV 16 (N = 47)

42

27

24

15

9

6

4

5

3

3

2

   HPV 18 (N = 6)

5

2

1

1

2

0

1

1

1

0

1

   Multiple (N = 11)

8

7

3

2

1

0

0

2

2

0

1

   Others (N = 16)

12

9

8

5

2

3

0

0

1

1

1

significance

P = 0.543

P = 0.740

P = 0.280

P = 0.792

P = 0.560

P = 0.467

P = 0.365

P = 0.288

P = 0.327

P = 1.000

P = 0.412

MSI

           

   MSS (N = 30)

26

20

17

4

2

3

1

2

5

4

2

   MSI-L (N = 9)

9

6

4

2

1

2

1

0

1

0

2

   MSI-H (N = 9)

8

2

3

3

4

0

1

3

1

0

1

Significance

P = 0.516

P = 0.065

P = 0.513

P = 0.434

P = 0.023

P = 1.000

P = 0.313

P = 0.079

P = 1.000

P = 0.443

P = 0.266

  1. P value corresponds to the P value from the Fisher's Exact test for the first two rows and for the P value from the Analysis of Variance for the last 3 rows. ¶Only patients with at least 5 months follow-up and treatment were considered and patients with treatment unknown or no treatment were excluded. SCC, squamous cell carcinoma; AC, adenocarcinoma; MSS, microsatellite stable; MSI-L, microsatellite instability low; MSI-H, microsatellite instability high; DOC, died of cancer; PR, partial response